Associations - Mucosal Melanoma

CANCER:

Mucosal Melanoma

Related cancers:

‹

Melanoma (792)

Ocular Melanoma (77)

Uveal Melanoma (74)

Cutaneous Melanoma (70)

Melanoma (792)

Ocular Melanoma (77)

Uveal Melanoma (74)

Cutaneous Melanoma (70)

›

No biomarker No biomarker	Mucosal Melanoma Mucosal Melanoma	toripalimab Sensitive: B - Late Trials toripalimab Sensitive : B
MDM2 amplification MDM2 amplification	Mucosal Melanoma Mucosal Melanoma	ipilimumab Resistant: C3 – Early Trials ipilimumab Resistant : C3
MDM4 amplification MDM4 amplification	Mucosal Melanoma Mucosal Melanoma	ipilimumab Resistant: C3 – Early Trials ipilimumab Resistant : C3
MDM2 amplification MDM2 amplification	Mucosal Melanoma Mucosal Melanoma	nivolumab + ipilimumab Resistant: C3 – Early Trials nivolumab + ipilimumab Resistant : C3
MDM2 amplification MDM2 amplification	Mucosal Melanoma Mucosal Melanoma	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3
MDM4 amplification MDM4 amplification	Mucosal Melanoma Mucosal Melanoma	nivolumab + ipilimumab Resistant: C3 – Early Trials nivolumab + ipilimumab Resistant : C3
MDM4 amplification MDM4 amplification	Mucosal Melanoma Mucosal Melanoma	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3
EGFR amplification EGFR amplification	Mucosal Melanoma Mucosal Melanoma	ipilimumab Resistant: C3 – Early Trials ipilimumab Resistant : C3
EGFR amplification EGFR amplification	Mucosal Melanoma Mucosal Melanoma	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3
EGFR amplification EGFR amplification	Mucosal Melanoma Mucosal Melanoma	nivolumab + ipilimumab Resistant: C3 – Early Trials nivolumab + ipilimumab Resistant : C3
EGFR amplification EGFR amplification	Mucosal Melanoma Mucosal Melanoma	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3
MDM4 amplification MDM4 amplification	Mucosal Melanoma Mucosal Melanoma	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3
MDM2 amplification MDM2 amplification	Mucosal Melanoma Mucosal Melanoma	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3
KIT L576P KIT L576P	Mucosal Melanoma Mucosal Melanoma	sorafenib Resistant: C4 – Case Studies sorafenib Resistant : C4
KIT L576P KIT L576P	Mucosal Melanoma Mucosal Melanoma	temsirolimus Resistant: C4 – Case Studies temsirolimus Resistant : C4
KIT L576P KIT L576P	Mucosal Melanoma Mucosal Melanoma	imatinib Resistant: C4 – Case Studies imatinib Resistant : C4

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES